State of New Jersey Common Pension Fund D maintained its position in shares of Incyte Corporation (NASDAQ:INCY) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 100,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. State of New Jersey Common Pension Fund D’s holdings in Incyte Corporation were worth $12,591,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Grandfield & Dodd LLC boosted its position in shares of Incyte Corporation by 0.7% in the first quarter. Grandfield & Dodd LLC now owns 7,298 shares of the biopharmaceutical company’s stock worth $976,000 after buying an additional 50 shares during the last quarter. IFP Advisors Inc boosted its position in shares of Incyte Corporation by 6.8% in the first quarter. IFP Advisors Inc now owns 1,043 shares of the biopharmaceutical company’s stock worth $139,000 after buying an additional 66 shares during the last quarter. State of Alaska Department of Revenue boosted its position in shares of Incyte Corporation by 5.4% in the second quarter. State of Alaska Department of Revenue now owns 2,292 shares of the biopharmaceutical company’s stock worth $288,000 after buying an additional 117 shares during the last quarter. Fisher Asset Management LLC boosted its position in shares of Incyte Corporation by 0.9% in the first quarter. Fisher Asset Management LLC now owns 15,050 shares of the biopharmaceutical company’s stock worth $2,012,000 after buying an additional 133 shares during the last quarter. Finally, Eqis Capital Management Inc. boosted its position in shares of Incyte Corporation by 0.7% in the second quarter. Eqis Capital Management Inc. now owns 19,811 shares of the biopharmaceutical company’s stock worth $2,494,000 after buying an additional 135 shares during the last quarter. 91.73% of the stock is owned by institutional investors and hedge funds.

Shares of Incyte Corporation (NASDAQ:INCY) opened at 130.70 on Wednesday. The company’s market cap is $26.89 billion. The stock has a 50 day moving average of $130.84 and a 200 day moving average of $128.99. Incyte Corporation has a 12-month low of $75.52 and a 12-month high of $153.15.

Incyte Corporation (NASDAQ:INCY) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $326.40 million during the quarter, compared to analyst estimates of $318.45 million. Incyte Corporation had a negative net margin of 11.77% and a negative return on equity of 21.57%. The firm’s revenue was up 32.5% compared to the same quarter last year. During the same period last year, the business earned $0.18 EPS. Analysts forecast that Incyte Corporation will post ($0.85) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was first posted by Daily Political and is the property of of Daily Political. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.dailypolitical.com/2017/08/09/state-of-new-jersey-common-pension-fund-d-has-12591000-stake-in-incyte-corporation-nasdaqincy.html.

A number of equities analysts recently commented on the stock. TheStreet raised shares of Incyte Corporation from a “d+” rating to a “c” rating in a research note on Wednesday, May 24th. Cowen and Company reaffirmed a “buy” rating on shares of Incyte Corporation in a research note on Monday, June 5th. Credit Suisse Group reaffirmed a “buy” rating on shares of Incyte Corporation in a research note on Saturday, June 10th. Zacks Investment Research raised shares of Incyte Corporation from a “sell” rating to a “hold” rating in a research note on Tuesday, April 18th. Finally, Raymond James Financial, Inc. reaffirmed a “hold” rating on shares of Incyte Corporation in a research note on Monday, April 17th. Seven analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $140.39.

In related news, CFO David W. Gryska sold 16,756 shares of the firm’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $116.60, for a total value of $1,953,749.60. Following the sale, the chief financial officer now owns 35,771 shares of the company’s stock, valued at $4,170,898.60. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Jean Jacques Bienaime bought 500 shares of Incyte Corporation stock in a transaction that occurred on Monday, May 15th. The stock was purchased at an average cost of $115.00 per share, for a total transaction of $57,500.00. Following the acquisition, the director now owns 4,177 shares of the company’s stock, valued at $480,355. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 48,183 shares of company stock worth $5,976,946. 17.70% of the stock is owned by corporate insiders.

Incyte Corporation Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY).

Institutional Ownership by Quarter for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.